India, March 31 -- The company has recently secured financing of Rs 648 crore from the Union Bank of India. What are the major plans in utilising these funds?

The capital is being deployed across three strategic priorities: capacity expansion, quality and regulatory excellence, and innovation-led manufacturing. At the core is the rapid development of our single-use commercial biologics facility in Pipan, Gujarat, with a planned capacity of up to 50,000 litres. This facility is designed to enable commercial-scale production of complex biologics and reinforce India's role in advanced biopharmaceutical manufacturing. We are also advancing digital manufacturing, automation, and data-enabled process control to drive efficiency, consistency, a...